知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 2025年1-8月，江西省工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为19367 个，和上年同期相比，增加了572个，同比增长3.04%，占全国的比重为3.71%。 2016-2025年1-8月江西省工业企业数统计图 数据来源：国家统计局，智研咨询整理 上市公司：江西铜业（600362），安源煤业（600397），九丰能源（605090），中国稀土（000831）， 仁和药业（000650），富祥药业（300497），同和药业（300636），江中药业（600750），煌上煌 （002695），甘源食品（002991），阳光乳业（001318），百胜智能（301083），南矿集团 （001360），江铃汽车（000550） 相关报告：智 ...

Core Viewpoint - The new Company Law, effective from July 1, 2024, allows shareholders to not only access but also copy shareholder information, raising concerns about the sensitivity of shareholder registers and the need for regulations to balance shareholder rights and company operations [1][4][8]. Group 1: Shareholder Rights and Regulations - The new Company Law stipulates that shareholders have the right to access and copy the company’s articles of association and shareholder register [1][4]. - Currently, only a few A-share listed companies have established a system for accessing shareholder registers, indicating a need for further market development to balance shareholder rights and company operations [1][4]. - There are discrepancies among listed companies regarding the interpretation of shareholder access to the shareholder register, with some allowing access to personal holding information only, while others permit broader access [4][5][9]. Group 2: Case of Shareholder Dispute - A notable incident involved a well-known investor, Xie Kai, who claimed to have faced verbal abuse from a lawyer while attempting to access the shareholder register of *ST Lihang, highlighting tensions between shareholders and company representatives [2][3]. - Xie Kai, known for his significant investments and past successes, has shown interest in various Sichuan-listed companies, although he was not listed among the top shareholders of *ST Lihang as of mid-2025 [2][3]. Group 3: Access Methods and Company Policies - Companies have varied policies regarding how shareholders can access the shareholder register, with some requiring in-person visits and others allowing remote access after verifying shareholder identity [5][7][10]. - Certain companies, like *ST Lihang, require shareholders to sign confidentiality agreements and provide proof of ownership before accessing the register, emphasizing the importance of protecting sensitive information [7][10]. - The establishment of internal regulations by companies, such as the one by Chuangyuan Xinke, aims to provide clear guidelines for accessing and copying shareholder registers while ensuring confidentiality [10]. Group 4: Balancing Interests - The potential for conflicts arises from the sensitive nature of shareholder registers, necessitating a balance between shareholder rights and the operational efficiency of companies [8][9]. - Legal experts suggest that unrestricted access to shareholder information could lead to unfair practices, advocating for a structured approach to managing shareholder inquiries [8][9]. - Recommendations include defining the boundaries of access to shareholder registers and implementing measures to protect sensitive data while ensuring fair market practices [9].

Core Viewpoint - The new Company Law, effective from July 1, 2024, allows shareholders to not only access but also copy shareholder information, raising concerns about the sensitivity of shareholder registers and the need for regulations to balance shareholder rights and company operations [1][4]. Group 1: Shareholder Rights and Regulations - The new Company Law stipulates that shareholders have the right to access and copy the company’s articles of association and shareholder register [1][4]. - Currently, only a few listed companies have established a system for accessing shareholder registers, indicating a need for further market work to balance shareholder rights and company operations [1][4]. - There are discrepancies among listed companies regarding the interpretation of shareholders' rights to access the shareholder register, with some companies allowing access to personal holding information only, while others permit broader access [4][5][9]. Group 2: Case of Shareholder Dispute - A well-known investor, Xie Kai, faced verbal abuse from a lawyer representing a listed company when he attempted to exercise his right to access the shareholder register, highlighting tensions between shareholders and company representatives [2][3]. - Xie Kai, who has a significant presence in the capital market, has shown interest in various listed companies, although he was not listed among the top shareholders of *ST Lihang as of mid-2025 [2][3]. Group 3: Access Methods and Company Policies - Companies have varied policies regarding how shareholders can access the shareholder register, with some requiring in-person visits and others allowing remote access after verifying shareholder identity [5][7][10]. - Certain companies mandate that shareholders sign confidentiality agreements and provide proof of ownership before accessing the register, emphasizing the importance of protecting sensitive information [7][10]. Group 4: Balancing Interests - The issue of accessing shareholder registers involves balancing the rights of shareholders with the operational needs of companies and the fairness of securities trading [8][9]. - Legal experts suggest that unrestricted access to shareholder information could lead to unfair practices, advocating for regulations that require shareholders to demonstrate legitimate purposes for accessing such information [8][9].

Group 1 - The core point of the article is that Tonghe Pharmaceutical has received a patent for a new intermediate related to Resmetirom, which may enhance its product offerings and market position [1] - The company reported that for the first half of 2025, its revenue composition is heavily weighted towards pharmaceutical manufacturing, accounting for 99.51% of total revenue, with other businesses contributing only 0.49% [1] - As of the report date, Tonghe Pharmaceutical has a market capitalization of 3.7 billion yuan [1]

证券代码：300636 证券简称：同和药业 公告编号：2025-050 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于近日收到国 家知识产权局颁发的发明专利证书，具体情况如下： 发明名称：一种Resmetirom中间体及其制备方法以及中间体III 的制备方法 江西同和药业股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 本发明提供一种瑞司美替罗新的中间体化合物及其制备方法，以 及将其用于制备瑞司美替罗关键中间体III的方法，该新中间体化合 物的应用可显著降低瑞司美替罗关键中间体III的生产成本和生产周 期。 上述发明专利的取得不会对公司近期生产经营产生重大影响，但 有利于强化公司自主知识产权技术优势，完善知识产权保护体系，从 而增强公司核心竞争力。 特此公告。 江西同和药业股份有限公司董事会 二〇二五年九月十九日 1/ 1 专利号：ZL 2023 1 1118581.4 专利类型：发明专利 专利申请日：2023.09.01 授权公告日：2025.09.19 专利权人：江西同和药业股份有限公司 本发明涉及公司产品瑞司美替罗 ...

Core Viewpoint - The company, Tonghua Dongbao Pharmaceutical, has received a revised Certificate of Suitability (CEP) for its Ticagrelor active pharmaceutical ingredient from the European Directorate for the Quality of Medicines (EDQM), effective from September 12, 2025, due to the addition of a new production workshop [1] Group 1 - The revised CEP indicates compliance with European pharmacopoeia standards, which is crucial for market access in Europe [1] - The change in the certificate is a strategic move to enhance production capacity and meet regulatory requirements [1] - The new production facility is expected to support the company's growth in the European market [1]

Core Viewpoint - The company, Tonghe Pharmaceutical, has received an updated Certificate of Suitability (CEP) from the European Medicines Agency for its raw material drug, Ticagrelor, due to the addition of a new production facility, effective from September 12, 2025 [1] Group 1: Company Information - Tonghe Pharmaceutical announced the receipt of the updated CEP for Ticagrelor, a novel selective small-molecule anticoagulant [1] - The updated certificate is a result of the company's expansion with a new production workshop [1] Group 2: Product Details - Ticagrelor is designed to block platelet activation, used for treating acute coronary syndrome patients, and aims to reduce the occurrence of thrombotic cardiovascular diseases [1] - The drug is characterized by its rapid and potent effects [1]

Group 1 - The company, Tonghe Pharmaceutical (300636.SZ), has received a revised Certificate of Suitability (CEP) for the raw material drug Ticagrelor from the European Directorate for the Quality of Medicines (EDQM) [1] - The revision is due to the addition of a new production workshop, and the certification scope includes Ticagrelor raw material [1] - The revised certificate will be effective from September 12, 2025 [1]

Core Viewpoint - The company has received a revised Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor from the European Directorate for the Quality of Medicines (EDQM), effective from September 12, 2025, due to the addition of a new production facility [1]. Group 1 - The company announced the receipt of the updated CEP for Ticagrelor active pharmaceutical ingredient [1]. - The revision of the CEP is primarily due to the establishment of a new production workshop [1]. - The effective date for the revised certificate is set for September 12, 2025 [1].

格隆汇9月16日丨同和药业(300636.SZ)公布，近日收到欧洲药品质量管理局（EDQM）颁发的变更后的 替格瑞洛原料药欧洲药典适应性证书(CEP)，本次变更主要原因为公司新增生产车间，变更后的证书自 2025年9月12日起生效。替格瑞洛是一种新型、具有选择性的小分子抗凝血药，可以阻断血小板活化， 用于治疗急性冠脉综合征患者，减少血栓性心血管疾病的发生，具有快速、强效的特点。公司替格瑞洛 产品新增生产车间获得EDQM批准，标志着公司替格瑞洛原料药在欧洲市场的供应能力进一步提升，将 对公司维持和扩大国际市场业务起到积极作用。 ...